insights_auto
Miks on 4142 langenud? 2,35%?
Uurige põhjalikumaltchevron_right
4142:TPE
Adimmune Corp
16,60Â NT$
arrow_downward
−2,35%(−0,40) 1 p
5. nov, 13:30:06 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
17,15Â NT$
Kõrge
17,20Â NT$
Madal
16,60Â NT$
Turu kapit.
7,13Â mld
Keskm. maht
1,07Â mln
Maht
1,16Â mln
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Ava
17,15Â NT$
Kõrge
17,20Â NT$
Madal
16,60Â NT$
Turu kapit.
7,13Â mld
Keskm. maht
1,07Â mln
Maht
1,16Â mln
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
Barchart.com
·
43 minuti eest
ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026
Yahoo Finance
·
34 minuti eest
Steven Madden (NASDAQ:SHOO) reports Q3 2026 in line with expectations
The Motley Fool
·
53 minuti eest
3 Stocks Yielding Triple the S&P 500 to Buy in November
ABC News - Breaking News, Latest News and Videos
·
22 tunni eest
Dow closes up 1,500 points as Democrats take control of Congress
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta